Hims & Hers Health, Inc. Class A Common Stock (NY:HIMS)

The Law Offices of Frank R. Cruz Announces Investigation of Hims & Hers Health, Inc. (HIMS) on Behalf of Investors

February 25, 2026

From The Law Offices of Frank R. Cruz

HIMS Stock Plummets After Wall Street Downgrade, Price Target Cuts Following 'Disappointing' Q4 Report ↗

February 24, 2026

HIMS stock is currently trading at levels last seen in September 2024 and has fallen over 50% year-to-date.

Hims & Hers Health Inc (NYSE:HIMS) Stock Falls on Weak Q1 2026 Revenue Guidance Despite Q4 Earnings Beat ↗

Topics Artificial Intelligence

February 23, 2026

Via Chartmill

HIMS Stock Plunges 8 Straight Days: Is The GLP-1 Fallout Already Priced In? ↗

February 11, 2026

As of February 24, 2026, the market narrative surrounding Hims & Hers Health (NYSE: HIMS) has become a stark "tale of two tapes." On one hand, the digital health disruptor recently reported a robust Q4...

Hims & Hers Health (HIMS): Decoding the Q4 Earnings Beat vs. the SEC GLP-1 Investigation

February 24, 2026

Via Finterra

Topics Earnings Economy Initial Public Offering

Nasdaq, S&P 500 Futures Steady After AI Fears Roil Tech: Why IBM, NVDA, NFLX, HIMS, PFE Are On Traders' Radar Today ↗

February 24, 2026

Data from Stocktwits indicated retail sentiment on SPY and QQQ remained ‘bearish’ on Stocktwits.

The company reiterated its longer-term targets of at least $6.5 billion in revenue and $1.3 billion in adjusted EBITDA by 2030.

Topics Artificial Intelligence ETFs Government

HIMS Stock Slumps Nearly 10% After-Hours: How CEO Dudum Plans To Offset GLP-1 Risk ↗

February 23, 2026

Hims & Hers (HIMS) Earnings Call Transcript

Topics Earnings

Hims & Hers (HIMS) Earnings Call Transcript ↗

February 23, 2026

Hims & Hers Health Inc (NYSE:HIMS) reports financial results for the fourth quarter after the market close on Monday.

Topics Earnings

Hims & Hers Health Reports Mixed Q4 Earnings, Subscribers Cross 2.5 Million ↗

February 23, 2026

Via Benzinga

Hims & Hers Health’s (NYSE:HIMS) Q4 CY2025 Earnings Results: Revenue In Line With Expectations

February 23, 2026

Telehealth company Hims & Hers Health (NYSE:HIMS) met Wall Street’s revenue expectations in Q4 CY2025, with sales up 28.4% year on year to $617.8 million. On the other hand, next quarter’s revenue...

Hims & Hers Health, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results

February 23, 2026

From Hims & Hers

High Volatility and Earnings Crossroads: A Deep Dive into Hims & Hers Health (HIMS) in 2026

February 23, 2026

As of February 23, 2026, Hims & Hers Health, Inc. (NYSE: HIMS) finds itself at a critical crossroads that has sent shockwaves through the telehealth and pharmaceutical sectors. Once the darling of the...

Via Finterra

Topics Artificial Intelligence Intellectual Property Lawsuit

HIMS Stock Short Interest At Record Levels Ahead Of Q4 Earnings: What Are Bears Betting Against? ↗

February 23, 2026

Short interest climbed from about 18.5% on Jan.1 to 33.7% by Monday.

Telehealth company Hims & Hers Health (NYSE:HIMS) will be announcing earnings results this Monday after market close. Here’s what to look for.

What To Expect From Hims & Hers Health’s (HIMS) Q4 Earnings

February 21, 2026

Hims & Hers is acquiring Eucalyptus and spreading its wings internationally.

Topics Artificial Intelligence Economy World Trade

Hims & Hers in Free Fall: Why Analysts See Nearly 150% Upside ↗

February 21, 2026

Via MarketBeat

Hims & Hers HUGE Acquisition News! ↗

February 19, 2026

Hims & Hers Health Makes Australia, Japan Foray With $1.15 Billion Eucalyptus Acquisition ↗

February 19, 2026

Hims & Hers Health, Inc. (HIMS) announced on Thursday that it has signed a definitive agreement to acquire Eucalyptus in a deal valued at up to $1.15 billion.

Hims & Hers Announces Agreement to Acquire Eucalyptus, Accelerating Its Vision to Become the Leading Global Consumer Health Platform

February 19, 2026

From Hims & Hers

HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation with the Schall Law Firm

February 18, 2026

From Schall Law

Via GlobeNewswire

2 Profitable Stocks on Our Watchlist and 1 We Ignore

February 16, 2026

Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.

Acadia Healthcare, Hims & Hers Health, RadNet, Halozyme Therapeutics, and Privia Health Shares Are Soaring, What You Need To Know

February 13, 2026

A number of stocks jumped in the afternoon session after a softer-than-expected inflation report fueled hopes for interest rate cuts by the Federal Reserve. The January Consumer Price Index (CPI), a...

Hoth Therapeutics's GDNF Treatment Shows Superior Efficacy Over Wegovy, Ozempic In Preclinical Trial ↗

Topics Economy

February 10, 2026

The company announced positive preclinical results from a study evaluating GDNF as a potential treatment for obesity and metabolic-associated steatotic liver disease.

Today is February 10, 2026. The telehealth landscape stands at a historic inflection point, and no company better embodies this volatility than Hims & Hers Health, Inc. (NYSE: HIMS). After a meteoric...

The Vertical Integration of Wellness: A Deep Dive into Hims & Hers Health (HIMS)

February 10, 2026

Via Finterra

Topics Artificial Intelligence Intellectual Property Lawsuit

Stocks making big moves yesterday: Shopify, Snowflake, Ryan Specialty, Merchants Bancorp, and Hims & Hers Health

February 10, 2026

Check out the companies making headlines yesterday:

Today, Feb. 9, 2026, investors are reevaluating Hims & Hers after it pulled its weight-loss pill, facing legal action and FDA scrutiny.

Topics Stocks

Dow 50,000 is No Longer a Mirage, but the "Accounting Ghost" Haunts Tech ↗

February 10, 2026

Via Chartmill

Topics Stocks

Stock Market Today, Feb. 9: Hims & Hers Health Drops 16% on Novo Nordisk Lawsuit ↗

February 09, 2026

Hims & Hers Collapses After FDA Vows to Restrict Copycat GLP-1 Pill. Is the Stock Toast? ↗

Topics Artificial Intelligence Lawsuit Stocks

February 09, 2026

Hims & Hers could face difficulty in the future in selling copycat GLP-1 drugs.

HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation with the Schall Law Firm

Topics Intellectual Property Lawsuit

February 09, 2026

From The Schall Law Firm

These stocks have been going in opposite directions of late, but that doesn't mean that trend will continue.

Novo Nordisk vs. Eli Lilly: What's the Better Long-Term Investment? ↗

February 09, 2026